BPC-157 for Shoulder Injury: What the Rotator Cuff Research Actually Shows
A 2014 study from the University of Zagreb showed BPC-157 restored full functional recovery in rats with surgically created rotator cuff tears. The treated rats regained mobility, muscle strength, and tendon structure that closely matched healthy controls. A 2025 systematic review of 36 preclinical studies confirmed BPC-157 promotes tendon, ligament, and muscle healing through angiogenesis and growth factor modulation. But here is the catch: zero controlled human trials exist for shoulder injuries. Everything below is animal data and mechanistic theory. That matters.
Rotator cuff injuries account for roughly 4.5 million physician visits per year in the United States. Partial and full-thickness tears affect anywhere from 13% to 32% of the general population, with prevalence climbing sharply after age 50. Standard treatment ranges from physical therapy and corticosteroid injections to arthroscopic surgery, with recovery timelines stretching from four months to over a year depending on severity.
Against that backdrop, BPC-157 has attracted serious attention from both researchers and athletes looking for faster healing options. But the gap between promising rat data and proven human outcomes is wider than most peptide websites will tell you. This guide walks through what the research actually says, where it falls short, and what that means for anyone considering BPC-157 for a shoulder injury.
